Payment overview · 2025
General Payments
$242.26
12 reported records · 7 companies
Healthcare provider profile · identity verified
Vesna Solheim, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MURRELLS INLET, SC · NPI 1528043528
Verified facts
What the public records show
CMS Open Payments records show Vesna Solheim, M.D. received $242.26 in general payments during 2025 across 12 reported records.
Corcept Therapeutics accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $71.58 | 29.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.07 | 15.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.62 | 14.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.28 | 12.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.43 | 10.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.28 | 9.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.00 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $242.26 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $71.58 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.07 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $38.07 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.28 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.28 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 76 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
99 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 645 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 585 | 185 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 450 | 157 |
| Omeprazole | Omeprazole | 361 | 123 |
| Losartan Potassium | Losartan Potassium | 350 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 301 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 84 |
| Ozempic | Semaglutide | 259 | 41 |
| Alprazolam | Alprazolam | 258 | 67 |
| Gabapentin | Gabapentin | 248 | 91 |
| Metformin Hcl Er | Metformin Hcl | 248 | 72 |
| Mounjaro | Tirzepatide | 244 | 36 |
| Simvastatin | Simvastatin | 227 | 74 |
| Lisinopril | Lisinopril | 213 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 205 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 72 |
| Tramadol Hcl | Tramadol Hcl | 188 | 61 |
| Trazodone Hcl | Trazodone Hcl | 187 | 64 |
| Sertraline Hcl | Sertraline Hcl | 158 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 56 |
| Glipizide Er | Glipizide | 139 | 41 |
| Furosemide | Furosemide | 137 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 43 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 119 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 35 |
| Allopurinol | Allopurinol | 114 | 37 |
| Famotidine | Famotidine | 112 | 46 |
| Metformin Hcl | Metformin Hcl | 110 | 36 |
| Meloxicam | Meloxicam | 108 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 48 |
| Lorazepam | Lorazepam | 105 | 29 |
| Ezetimibe | Ezetimibe | 103 | 37 |
| Farxiga | Dapagliflozin Propanediol | 100 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 35 |
| Synthroid | Levothyroxine Sodium | 99 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 31 |
| Celecoxib | Celecoxib | 89 | 34 |
| Trulicity | Dulaglutide | 88 | 15 |
| Azithromycin | Azithromycin | 86 | 74 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 85 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 28 |
| Montelukast Sodium | Montelukast Sodium | 80 | 31 |
| Valsartan | Valsartan | 80 | 35 |
| Bupropion Xl | Bupropion Hcl | 79 | 24 |
| Donepezil Hcl | Donepezil Hcl | 76 | 28 |
| Eliquis | Apixaban | 76 | 22 |
| Potassium Chloride | Potassium Chloride | 72 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 23 |
| Atenolol | Atenolol | 71 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 30 |
| Clonazepam | Clonazepam | 70 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 67 | 22 |
| Prednisone | Prednisone | 65 | 44 |
| Temazepam | Temazepam | 65 | 19 |
| Eszopiclone | Eszopiclone | 62 | 16 |
| Methylprednisolone | Methylprednisolone | 62 | 58 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 22 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 47 |
| Fluconazole | Fluconazole | 57 | 41 |
| Ibandronate Sodium | Ibandronate Sodium | 56 | 19 |
| Estradiol | Estradiol | 55 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 18 |
| Meclizine Hcl | Meclizine Hcl | 54 | 29 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Primidone | Primidone | 50 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 43 |
| Diazepam | Diazepam | 49 | 21 |
| Telmisartan | Telmisartan | 49 | 13 |
| Buspirone Hcl | Buspirone Hcl | 48 | 16 |
| Carvedilol | Carvedilol | 48 | 14 |
| Jardiance | Empagliflozin | 47 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 21 |
| Ibuprofen | Ibuprofen | 43 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 43 | 16 |
| Pregabalin | Pregabalin | 43 | 16 |
| Fenofibrate | Fenofibrate | 42 | 13 |
| Lansoprazole | Lansoprazole | 42 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 12 |
| Valacyclovir | Valacyclovir Hcl | 40 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 11 |
| Propranolol Hcl | Propranolol Hcl | 39 | 15 |
| Glimepiride | Glimepiride | 38 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 27 |
| Aripiprazole | Aripiprazole | 37 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 17 |
| Amoxicillin | Amoxicillin | 35 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 12 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 14 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 22 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 16 |
| Glipizide | Glipizide | 29 | 11 |
| Mupirocin | Mupirocin | 29 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 11 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 16 |
| Levofloxacin | Levofloxacin | 25 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 22 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | 11 |
| Linzess | Linaclotide | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Np Thyroid | Thyroid,pork | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $242.26 · 12 records | Corcept Therapeutics | AIRSUPRA, AREXVY, ELIQUIS, FARXIGA, Korlym, LEQVIO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SHINGRIX, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error